More partnerships forged to boost China's genomic and regen medicine focus
This article was originally published in Clinica
In line with the government’s upcoming 13th Five Year Plan, China is making efforts to promote and commercialize genomic research findings and regenerative medicine research. Recent collaborative initiatives launched jointly by the government, academia and industry are already aiming to bring clinical solutions in these areas to Chinese patients.
You may also be interested in...
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.